Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 15/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 15/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 15/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.65 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.65 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.65 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309994 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL8242401 | 0.94 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL8245040 | 0.93 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949983 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL29855629 | 0.87 | HDAC1 (0.77) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL211880 | 0.87 | HDAC1 (0.77) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL211881 | 0.87 | HDAC1 (0.77) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949807 | 0.86 | HDAC1 (0.80) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL13949916 | 0.86 | HDAC1 (0.76) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL16806648 | 0.86 | HDAC1 (0.76) | HDAC1HDAC3HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215813-A1 | HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS | NOVARTIS AG (CH) | 2009-08-27 | — | — | US | claimed |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | NOVARTIS AG | 2009-01-08 | — | — | US | claimed |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | SECURA BIO, INC. | 2008-07-24 | — | — | US | claimed |
| EP-1915141-A1 | METHOD OF USE OF DEACETYLASE INHIBITORS | Novartis AG (CH) | 2008-04-30 | — | — | EP | claimed |
| EP-1870399-A1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2007-12-26 | — | — | EP | claimed |
| US-20070258972-A1 | Combination of a Histone Deacetylase Inhibitor with a Death Receptor Ligand | ATADJA PETER W | 2007-11-08 | — | — | US | claimed |
| EP-1318980-B1 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-10-31 | — | — | EP | claimed |
| US-20070191338-A1 | Combinations comprising staurosporines | ATADJA PETER W | 2007-08-16 | — | — | US | claimed |
| US-20070123580-A1 | Combination of histone deacetylase inhibitors with chemotherapeutic agents | ATADJA PETER W | 2007-05-31 | — | — | US | claimed |
| WO-2007021682-A1 | METHOD OF USE OF DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-6833384-B2 | E. g., N-Hydroxy-3-(4-(((2-(1H-indol-3-yl)-ethyl)amino)-amino)methyl)-phenyl)-2E-2 -propenamide; histone deacetylase inhibitors; antiproliferative agents; antitumor agents; anticarcinogenic agents | NOVARTIS AG (CH) | 2004-12-21 | — | — | US | claimed |
| WO-2004103358-A2 | COMBINATION OF HISTONE DEACETYLASE INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | NOVARTIS AG (CH) | 2004-12-02 | — | — | WO | claimed |
| EP-1456664-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | Novartis AG (CH) | 2004-09-15 | — | — | EP | claimed |
| EP-1443967-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | Novartis AG (CH) | 2004-08-11 | — | — | EP | claimed |
| US-20040024067-A1 | Deacetylase inhibitors | ATHYRIUM OPPORTUNITIES III ACQUISITION LP | 2004-02-05 | — | — | US | claimed |
| EP-1318980-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | Novartis AG (CH) | 2003-06-18 | — | — | EP | claimed |
| WO-2003048774-A1 | USE OF ALPHA-TUBULIN ACETYLATION LEVELS AS A BIOMARKER FOR PROTEIN DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2003-06-12 | — | — | WO | claimed |
| WO-2003039599-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | claimed |
| US-20030018062-A1 | Deacetylase inhibitors | SECURA BIO, INC. | 2003-01-23 | — | — | US | claimed |
| WO-2002022577-A2 | HYDROXAMATE DERIVATIVES USEFUL AS DEACETYLASE INHIBITORS | NOVARTIS AG (CH) | 2002-03-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191338-A1 | Combinations comprising staurosporines | MCL1, FLT3, FLI1 | HDAC1 10/4885HDAC3 24/4885HDAC4 42/4885 |
| US-20070258972-A1 | Combination of a Histone Deacetylase Inhibitor with a Death Receptor Ligand | HDAC5, HDAC1, HDAC9 | HDAC1 2/4885HDAC3 5/4885HDAC4 9/4885 |
| US-20080176849-A1 | DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC4 6/4885 |
| US-20040024067-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC4 6/4885 |
| US-20090215813-A1 | HISTONE DEACETYLASE INHIBITORS AS IMMUNOSUPPRESSANTS | HDAC1, HDAC2, HDAC5 | HDAC1 1/4885HDAC3 9/4885HDAC4 8/4885 |
| US-20090012066-A1 | Method of Use of Deacetylase Inhibitors | HDAC3, HDAC5, HDAC1 | HDAC1 3/4885HDAC3 1/4885HDAC4 5/4885 |
| US-20030018062-A1 | Deacetylase inhibitors | HDAC1, HDAC3, HDAC6 | HDAC1 1/4885HDAC3 2/4885HDAC4 6/4885 |
| US-20070123580-A1 | Combination of histone deacetylase inhibitors with chemotherapeutic agents | HDAC1, HDAC9, HDAC5 | HDAC1 1/4885HDAC3 5/4885HDAC4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.